To include your compound in the COVID-19 Resource Center, submit it here.

NicVax: Preliminary Phase III data

Preliminary data from a double-blind, U.S. Phase III trial in 1,000 patients showed that NicVax missed the primary endpoint of significantly improving abstinence rate for 16 weeks ending at 12 months as measured

Read the full 332 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers